Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Edetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | EYA2 | O00167 | 1/20 | 0.64 |
| ▸ | APP | P05067 | 1/20 | 0.64 |
| ▸ | ACE | P12821 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 2/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | DRD1 | P21728 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL10639072 | 0.98 | TDP1 (0.67) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL21793 | 0.98 | TDP1 (0.67) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL840661 | 0.98 | TDP1 (0.67) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL3391953 | 0.98 | TDP1 (0.67) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL2557176 | 0.98 | TDP1 (0.67) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL5718746 | 0.95 | TDP1 (0.64) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL1132175 | 0.95 | TDP1 (0.64) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL10706256 | 0.95 | TDP1 (0.64) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL3888754 | 0.93 | TDP1 (0.74) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL153915 | 0.91 | TDP1 (0.58) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3927347-B1 | DRUG COMBINATION FOR USE IN A METHOD OF TREATING LIVER CANCER | MEDIVIR AB (SE) | 2023-12-27 | — | — | EP | disclosed |
| US-20220117983-A1 | METHODS FOR TREATING LIVER CANCERS USING AN ORALLY ADMINISTERED DIOXOLANE NUCLEOTIDE IN COMBINATION WITH AN ANTI-PD1 OR ANTI-PDL1 MONOCLONAL ANTIBODY | MEDIVIR AB (SE) | 2022-04-21 | — | — | US | disclosed |
| EP-3927347-A1 | METHODS FOR TREATING LIVER CANCERS USING AN ORALLY ADMINISTERED DIOXOLANE NUCLEOTIDE IN COMBINATION WITH AN ANTI-PD1 OR ANTI-PDL1 MONOCLONAL ANTIBODY | Medivir Aktiebolag (SE) | 2021-12-29 | — | — | EP | disclosed |
| US-10729778-B2 | Carrier-linked treprostinil prodrugs | ASCENDIS PHARMA A/S (DK) | 2020-08-04 | — | — | US | disclosed |
| US-20190105400-A1 | Carrier-Linked Treprostinil Prodrugs | ASCENDIS PHARMA A/S (DK) | 2019-04-11 | — | — | US | disclosed |
| US-9872864-B2 | Sustained release composition of prostacyclin | ASCENDIS PHARMA A/S (DK) | 2018-01-23 | — | — | US | disclosed |
| EP-3191104-A1 | METHODS FOR TREATING A DISEASE OR DISORDER USING ORAL FORMULATIONS OF CYTIDINE ANALOGS IN COMBINATION WITH AN ANTI-PD1 OR ANTI-PDL1 MONOCLONAL ANTIBODY | Celgene Corporation (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9561287-B2 | Carrier-linked treprostinil prodrugs | ASCENDIS PHARMA A/S (DK) | 2017-02-07 | — | — | US | disclosed |
| WO-2016040238-A1 | METHODS FOR TREATING A DISEASE OR DISORDER USING ORAL FORMULATIONS OF CYTIDINE ANALOGS IN COMBINATION WITH AN ANTI-PD1 OR ANTI-PDL1 MONOCLONAL ANTIBODY | CELGENE CORPORATION (US) | 2016-03-17 | — | — | WO | disclosed |
| WO-2015195786-A2 | METHODS FOR TREATING CANCERS USING ORAL FORMULATIONS OF CYTIDINE ANALOGS | CELGENE CORPORATION (US) | 2015-12-23 | — | — | WO | disclosed |
| EP-2741738-A1 | SUSTAINED RELEASE COMPOSITION OF PROSTACYCLIN | Ascendis Pharma A/S (DK) | 2014-06-18 | — | — | EP | disclosed |
| WO-2013067043-A1 | METHODS FOR TREATING CANCERS USING ORAL FORMULATIONS OF CYTIDINE ANALOGS | CELGENE CORPORATION (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013024052-A1 | CARRIER-LINKED TREPROSTINIL PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024053-A1 | CARRIER-LINKED PRODRUGS HAVING REVERSIBLE CARBOXYLIC ESTER LINKAGES | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024051-A1 | SUSTAINED RELEASE COMPOSITION OF PROSTACYCLIN | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| US-8105769-B2 | Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments | THE GENERAL HOSPITAL CORPORATION (US) | 2012-01-31 | — | — | US | disclosed |
| US-7964349-B2 | Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments | THE GENERAL HOSPITAL CORPORATION (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2299984-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009139888-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION (US) | 2009-11-19 | — | — | WO | disclosed |
| US-4534795-A | CATALYST, COMPLEXING AGENT; SELF-SETTING | FOSROC INTERNATIONAL LIMITED (GB) | 1985-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10729778-B2 | Carrier-linked treprostinil prodrugs | PAH, SLC16A1, SLC34A3 | ADRA2A 2031/4885TDP1 622/4885EYA2 4720/4885 |
| US-20220117983-A1 | METHODS FOR TREATING LIVER CANCERS USING AN ORALLY ADMINISTERED DIOXOLANE NUCLEOTIDE IN COMBINATION WITH AN ANTI-PD1 OR ANTI-PDL1 MONOCLONAL ANTIBODY | CD274, PDCD1LG2, PDCD1 | ADRA2A 903/4885TDP1 736/4885EYA2 3635/4885 |
| US-20190105400-A1 | Carrier-Linked Treprostinil Prodrugs | PAH, TK1, SLC16A1 | ADRA2A 1902/4885TDP1 636/4885EYA2 4610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.